Swiss Rockets AG announced today the founding of Rocketvax AG to rapidly develop an effective and save vaccine against SARS-CoV-2. The new vaccine is based on the inventor rights acquired from Gigabases Switzerland AG and our groundbreaking DNA synthesis technology.
"The development of a SARS-CoV-2 vaccine might be more complex than anticipated, and the first generation of vaccines may not provide the long-lasting, high-level protection that will be needed to end the many negative consequences of the global SARS-CoV-2 pandemic. A number of leading SARS-CoV-2 vaccine candidates use other viruses, such as adenoviruses tagged with just one coronavirus protein, particularly the spike protein which is required for the virus to enter cells. However, it is unlikely that these vaccines will induce strong and lasting protection against SARS-CoV-2. We believe that it is important to develop vaccines that cover as many SARS-CoV-2 proteins as possible but without any pathogenic potential" - Dr. Vladimir Cmiljanovic, Chairman and CEO of Swiss Rockets.
Genetic design of the second-generation vaccine is already running and we look forward for a very productive and exciting partnership!